Immunocore Holdings PLC Sponsored ADR $IMCR Stock Position Trimmed by Fiera Capital Corp

Fiera Capital Corp decreased its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 2.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 795,157 shares of the company’s stock after selling 17,917 shares during the period. Fiera Capital Corp owned approximately 1.58% of Immunocore worth $28,888,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in IMCR. Y Intercept Hong Kong Ltd bought a new position in shares of Immunocore in the second quarter worth $1,621,000. Acadian Asset Management LLC raised its stake in shares of Immunocore by 392.3% during the second quarter. Acadian Asset Management LLC now owns 90,798 shares of the company’s stock valued at $2,843,000 after purchasing an additional 72,355 shares in the last quarter. Eschler Asset Management LLP acquired a new stake in Immunocore in the second quarter worth about $1,255,000. Frazier Life Sciences Management L.P. grew its position in Immunocore by 27.8% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 384,782 shares of the company’s stock valued at $12,074,000 after buying an additional 83,612 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D bought a new position in Immunocore in the 2nd quarter valued at about $292,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Down 1.5%

Shares of Immunocore stock opened at $32.68 on Friday. Immunocore Holdings PLC Sponsored ADR has a 12-month low of $23.15 and a 12-month high of $40.71. The firm has a market capitalization of $1.65 billion, a PE ratio of -57.33 and a beta of 0.78. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The stock’s fifty day moving average is $33.81 and its 200-day moving average is $34.30.

Analyst Ratings Changes

IMCR has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, February 4th. Zacks Research upgraded shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Morgan Stanley upped their target price on Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Mizuho set a $38.00 price target on Immunocore in a research note on Thursday. Finally, Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $60.90.

Insiders Place Their Bets

In related news, insider David M. Berman sold 5,965 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the transaction, the insider directly owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. The trade was a 50.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bahija Jallal sold 11,474 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer owned 12,343 shares in the company, valued at approximately $399,296.05. This represents a 48.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 19,137 shares of company stock worth $619,082. Corporate insiders own 10.40% of the company’s stock.

Key Immunocore News

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst and institutional support: multiple brokers still carry buy/overweight views and the consensus average price target (~$60.90) sits well above the current market level, which can underpin upside if clinical or commercial progress resumes. MarketBeat IMCR Coverage
• Positive Sentiment: High institutional ownership (~84.5%): large, stable holders (Primecap, Bellevue, Tang Capital, Millennium, Armistice) can reduce free float and provide support over the medium term as long-term investors remain committed. MarketBeat IMCR Coverage
• Neutral Sentiment: Strong liquidity on the balance sheet: very high current and quick ratios (~6.0) reduce short-term solvency risk but are unlikely to drive near-term share moves absent new catalysts.
• Neutral Sentiment: Short-interest data appears inconsistent: the recent report shows effectively 0 shares short (and 0 days to cover), which is likely a reporting anomaly and should be treated cautiously rather than interpreted as a market signal.
• Neutral Sentiment: Lower-than-average intraday volume can amplify price moves on either positive or negative news; monitor volume for conviction on any follow-through.
• Negative Sentiment: Clustered insider selling: CEO Bahija Jallal sold 11,474 shares (~48% reduction in her stake) and several other senior insiders (David Berman, John Goll, Tina Leger) also sold large portions on the same day—a development that commonly pressures sentiment and can trigger short‑term selling. InsiderTrades: CEO Sells IMCR SEC Form 4 (Berman)

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.